Member Info for MisterPositive

Gaining traction already in the US market. Lot going on behind the scenes.

"the CARDIO inCode test is included on the U.S. Centers for Medicare and Medicaid Services (CMS) 2025 Clinical Laboratory Fee Schedule with an average reimbursement of approximately $500.

Direct Lab Partnerships: GENinCode has established direct, existing laboratory partnerships in the US, such as with California Irvine Labs, to drive initial test adoption.

Expanding Footprint: The company doubled its active US ordering sites from 20 to 40 in the first half of 2025 and aimed to exceed 60 by the end of 2025."

Current MCap £9m

CASH £4.5M

Not seen a set up like this for any Pharma stock for a very very long time.

Beautifuly poised for a SIGNIFICANT re-rate in coming days.

Been accumulating as many as possible funds permitting but also accept Market will NOT wait for any of us. Happy to pay more before it jumps to over +2p next week ahead of news.

Good luck everyone here and New comers.

MP

Before full US regulatory clearance, laboratories will be offered the test as a Lab Developed Test, a route that allows hospitals and clinics to run their own versions while the food and drug regulator completes its review.

Once GENinCode secures FDA medical-device approval, Thermo Fisher will begin manufacturing and selling the kit directly to laboratories and testing centres. A similar roll-out is planned in EMEA.

The tie-up is significant for a company of GENinCode’s size. Thermo Fisher’s QuantStudio 5 Dx real-time PCR system, on which the test is designed, is already widely installed, giving the test immediate reach. The partners expect to scale manufacturing as demand grows.

CARDIO inCode-Score uses a polygenic risk score to estimate a person’s inherited likelihood of coronary heart disease from a saliva or blood sample.

GENinCode says stronger genetic insight allows clinicians to target lifestyle advice or treatment earlier, helping to prevent severe events such as heart attacks. The test recently secured New York State licensure and is listed on the 2025 US clinical laboratory fee schedule at an average reimbursement of about $500.

Https://www.proactiveinvestors.co.uk/companies/news/1083760/genincode-surges-on-thermo-fisher-deal-to-roll-out-heart-disease-test-1083760.html?rel=scroll

This jumped to 4.02p in Dec 2025 on manufacturing & commercialisation deal with ThermoFisher Scientific.

Touched 5.50p next day

Expect Bigger move this time around.

MMs tried to grab few cheap shares.

That did not work.

They will need plan B....to take higher if they want to grab any shares.

Such a small no of shares in Free float.

With Pharma stocks anything is possible.

GENI is in prime position with a HUGE market

Estimates range from $10.5B to $30B market.

IMM went from 1.39p (low) to 19.40p (High) in just around 4 weeks last year.

Ask has jumped to 1.30 now ??

1.40 next...

Higher end @ 11.5p

Lower end @ 7.5p

BIG GAINS ahead....

Touched 5.50p back in Sep 2025

Drifted back because FDA news was to come Q1. So people went chasing rainbows elsewhere.

No reason why we cannot hit 7.5p at Lower end.

Could even test +10p this time around.

Been ticking higher on low volume.

With a bit of buying pressure and volume this can break past 1.50 - 1.60 in quick order even 1.80 ahead of news as Buyers start taking positions.

Just in December it did +100% in two days jumping from 2p to 4p

Expect lot higher this time. This is BIG news.

UCL hospital London soon to adopt it OR already done it I think.

Great summary and reminder of the prize here.

This will go straight to +10p when the news lands

Pharma stocks can Rocket 🚀 higher at lightning speed. This is going to make "Headlines".

Ticking higher on low volume. Imagine when volume goes up and Buyers start taking positions ahead of FDA update.

One of the best and cheapest Pharma stock around vs peers on risk vs rewards basis.

LOWEST MCap at below £9m (half is CASH) but with the BIGGEST upside in my opinion.

GENI worth a look in my opinion while we wait for NASDAQ listing here. Please DYOR

Tiger16

Are you still in GENI ?

One of best Pharma stock with MASSIVE upside vs its peers.

One of the lowest MCap (almost half is CASH).

Huge target market USA, Europe, ME, Africa and Latin America.

Cardiovascular device/test market to rise to $33b

Granted approval in NEW YORK State already.

$500 per test reimbursement revenue.

Manufacturing & Distribution deals signed up including with ThermoFisher (US giant).

30 - 50 Multi-bagger, may be more.

50% of the MCap here is just CASH.

Insane....

Mr 10% holder looking to Add more I think.

You do not just take almost 10% of the company without any due diligence and research.

Time for another Top Up

Or if RNS lands this week, will be over 2p in a flash

5% daily rise is fine by me.

In 10 days at this rate would be 2p

Just capturing 5% of the $10.5 billion US market would be $525m (£392m) = 52p

Current MCap around £8.7m ???

Not going to stay at this price for long.

At some point soon Market will wake up and take this higher with NO warning whatsoever. Some folks will then pop in and ask....whats going on here? 😁

Already approved in NEW YORK State.

$500 reimbursement income per test/device.

Only 100,000 units sold in NY State alone @ $500 each gives you revenues of US$50m

+1m units sold and revenue jumps to $500m

Mind boggles......Current MCap is crazy low

At this stage Pharma stocks command a premium

Market is sleeping and not really Cottoned on.

Wait till Mr Market wakes up !!!